Brokerages Set Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Target Price at $37.67

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $37.6667.

Several research firms recently weighed in on TEVA. Piper Sandler restated an “overweight” rating and issued a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. Jefferies Financial Group boosted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. The Goldman Sachs Group raised their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, Truist Financial boosted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th.

Insiders Place Their Bets

In related news, EVP Eliyahu Sharon Kalif sold 345,810 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the completion of the transaction, the executive vice president owned 57,478 shares of the company’s stock, valued at approximately $1,933,559.92. The trade was a 85.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard Daniell sold 17,295 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the sale, the executive vice president owned 85,755 shares of the company’s stock, valued at approximately $2,715,860.85. The trade was a 16.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 858,799 shares of company stock valued at $28,185,035 in the last ninety days. Company insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC boosted its holdings in Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after purchasing an additional 4,732 shares during the period. Focus Partners Wealth lifted its stake in shares of Teva Pharmaceutical Industries by 4.5% in the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after buying an additional 1,739 shares during the period. Bank of New York Mellon Corp grew its position in Teva Pharmaceutical Industries by 4.5% during the second quarter. Bank of New York Mellon Corp now owns 1,682,837 shares of the company’s stock worth $28,204,000 after buying an additional 73,141 shares in the last quarter. Metis Global Partners LLC increased its stake in Teva Pharmaceutical Industries by 12.8% during the second quarter. Metis Global Partners LLC now owns 15,401 shares of the company’s stock valued at $258,000 after acquiring an additional 1,749 shares during the period. Finally, Vise Technologies Inc. acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $326,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 3.2%

Shares of NYSE:TEVA opened at $29.47 on Friday. The stock has a market capitalization of $33.88 billion, a PE ratio of 24.56, a P/E/G ratio of 9.56 and a beta of 0.72. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $37.35. The firm has a fifty day moving average price of $32.88 and a 200 day moving average price of $26.82. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business’s revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.